Yoda Pharmaceuticals Inc.Taiwan Branch (Cayman)
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Yoda Pharmaceuticals Inc.Taiwan Branch (Cayman) leverages its AI-driven drug discovery platform, dedicating itself to addressing multiple unmet medical needs, exploring and developing highly potential and highly effective products to bring brand new hope to patients.
1. Neurological Diseases: YA-101 Multiple System Atrophy (MSA); YA-102 Parkinson's Disease (PD); YA-201 Alzheimer's Disease (AD)
2. Psychiatric Disorders: YA-301 Schizophrenia; YA-401 Autism
3. Cerebrovascular Diseases: YA-501 Ischemic Stroke; YA-502 Traumatic Brain Injury
1. Neurological Diseases: YA-101 Multiple System Atrophy (MSA); YA-102 Parkinson's Disease (PD); YA-201 Alzheimer's Disease (AD)
2. Psychiatric Disorders: YA-301 Schizophrenia; YA-401 Autism
3. Cerebrovascular Diseases: YA-501 Ischemic Stroke; YA-502 Traumatic Brain Injury
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60613513
Status
Active
Number of Employees
0
Total Paid-in
Capital
- (NT$)
Exit Status
Emerging Stock Exchange(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Yoda Pharmaceuticals Inc.Taiwan Branch (Cayman) was co-founded in 2019 by researchers and psychiatrists from National Taiwan University, National Yang Ming Chiao Tung University, and the National Health Research Institutes. Incubated from Taiwan's national programs and Stanford University's global SPARK program in the United States, it is a novel drug development company built on the foundation of artificial intelligence (AI) technology, focusing on the field of central nervous system (CNS) diseases. Its product under development, YA-101, was granted Orphan Drug Designation for Multiple System Atrophy (MSA) by the U.S. Food and Drug Administration (FDA) in 2022, and has already entered Phase II clinical trials. Yoda Pharmaceuticals Inc.Taiwan Branch (Cayman) currently has multiple novel drug R&D pipelines in the fields of neurological and psychiatric disorders, with indications including schizophrenia, Alzheimer's disease, and multiple system atrophy. Upholding the mission of filling unmet medical needs, the company is dedicated to bringing new treatment options to patients with psychiatric and neurodegenerative diseases who are in urgent need of innovative, effective, safe, and convenient medications.
The content above was translated by Ai
